Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 plus imatinib dose-finding study in advanced GIST after imatinib and sunitinib failure
NL-OMON35356Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Maximum tolerated dose and/or recommended Phase II dose. Started Apr 2012; status: active, not recruiting.
02
Drugs
buparlisibimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON35356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35356.